What you need to know
A number of JAK inhibitors are now approved for the treatment of rheumatic diseases in different settings, but questions remain about their long-term safety profiles and overall place in therapy.
Take a look below for in-depth discussion of the potential risks associated with JAK inhibitors and what these mean for rheumatologists, as well as news on the latest safety data and approvals for this class of drugs.
Stay informed with Medicine Matters
Get the latest developments in rheumatology delivered straight to your inbox
‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA
“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.
Safety snapshot: Upadacitinib in patients with psoriatic arthritis
Access our overview of the key safety data from the SELECT-PsA studies.
Laptop & magnifying glass/© Michail_Petrov-96 / Getty Images / iStock, Question mark illustration/© terovesalainen / stock.adobe.com, Approval timeline, Exclamation mark/© Pixabay, Approval/© Astrovector / stock.adobe.com